NCT06225752View on ClinicalTrials.gov

Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis

PHASE3RecruitingINTERVENTIONAL
Enrollment

5,452

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

October 31, 2026

Conditions
Ischemic StrokeTIA
Interventions
DRUG

Probucol

Inclusion Days 1-30: Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)

DRUG

Placebo probucol

Inclusion Days 1-30: Placebo Probucol 1000mg/day (500mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.) Inclusion Days 31 and beyond: Placebo Probucol 500mg/day (250mg per dose, twice daily, a minimum of 4 hours should elapse between each pair of doses.)

Trial Locations (1)

Unknown

RECRUITING

The First Affliated Hospital of Wannan Medical College, Wuhu

All Listed Sponsors
collaborator

Beijing Tiantan Hospital

OTHER

lead

First Affiliated Hospital of Wannan Medical College

OTHER